GlobeNewsWire · COAG · November 9, 2026

Hemab Therapeutics Initiates SOLARA, a Pivotal Phase 3 Trial of Sutacimig in Glanzmann Thrombasthenia

Get the app for more

Explore stock news, insights and company research.